Presented in part at the American Society of Hematology (ASH) 50th Annual Meeting, December 2008 and the ASH 54th Annual Meeting, December 2012.
Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study
Version of Record online: 25 APR 2014
© 2014 John Wiley & Sons Ltd
British Journal of Haematology
Volume 166, Issue 4, pages 514–520, August 2014
How to Cite
Evens, A. M., Smith, M. R., Lossos, I. S., Helenowski, I., Millenson, M., Winter, J. N., Rosen, S. T. and Gordon, L. I. (2014), Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study. British Journal of Haematology, 166: 514–520. doi: 10.1111/bjh.12915
- Issue online: 25 JUL 2014
- Version of Record online: 25 APR 2014
- Manuscript Accepted: 19 MAR 2014
- Manuscript Received: 6 FEB 2014
|bjh12915-sup-0001-TableS1.docx||Word document||103K||Table SI. Management of Bortezomib-Related Toxicities.|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.